Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Current Deferred Revenue (2022 - 2025)

Zymeworks' Current Deferred Revenue history spans 4 years, with the latest figure at $17.0 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 57.71% to $17.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.0 million, a 57.71% decrease, with the full-year FY2025 number at $17.0 million, down 57.71% from a year prior.
  • Current Deferred Revenue hit $17.0 million in Q4 2025 for Zymeworks, up from $3.2 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ZYME hit a ceiling of $40.2 million in Q4 2024 and a floor of $93000.0 in Q3 2023.
  • Historically, Current Deferred Revenue has averaged $16.3 million across 4 years, with a median of $11.3 million in 2024.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 99.72% in 2023 and later surged 29134.41% in 2024.
  • Tracing ZYME's Current Deferred Revenue over 4 years: stood at $32.9 million in 2022, then plummeted by 88.77% to $3.7 million in 2023, then soared by 986.49% to $40.2 million in 2024, then crashed by 57.71% to $17.0 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ZYME at $17.0 million in Q4 2025, $3.2 million in Q3 2025, and $3.8 million in Q2 2025.